The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Flixonase Allergy Relief 50 micrograms per dose Nasal Spray

Haleon Ireland LimitedPA0678/095/001

Main Information

Trade NameFlixonase Allergy Relief 50 micrograms per dose Nasal Spray
Active SubstancesFluticasone propionate
Dosage FormNasal spray, suspension
Licence HolderHaleon Ireland Limited
Licence NumberPA0678/095/001

Group Information

ATC CodeR01AD Corticosteroids
R01AD08 fluticasone


License statusAuthorised
Licence Issued02/05/2003
Legal statusProduct not subject to medical prescription
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to the general public
Conditions of LicenceProduct not subject to medical prescription if compliant with the following restrictions: pack containing not more than 3,000 mcg fluticasone proprionate, maximum period of treatment: 6 months, maximum dose: 100 mcg per nostril, maximum daily dose: 200 mcg per nostril, limited indications, pharmaceutical form: non-pressurised nasal spray, for use in adults and children not under 12 years.
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back